© 2023 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2023 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
September 06, 2022
The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.
September 03, 2022
Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.
September 02, 2022
Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.
September 01, 2022
There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.
August 30, 2022
A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.
August 26, 2022
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.
August 25, 2022
Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.